Search results
Showing 1501 to 1550 of 3041 results for all
Evidence-based recommendations on KardiaMobile for detecting atrial fibrillation.
Caris Molecular Intelligence for guiding cancer treatment (MIB120)
NICE has developed a medtech innovation briefing (MIB) on Caris Molecular Intelligence for guiding cancer treatment .
Early and metastatic HER2-positive breast cancer: subcutaneous trastuzumab (ESNM13)
Summary of the evidence on subcutaneous trastuzumab for HER2-positive breast cancer to inform local NHS planning and decision-making
Intravenous fluid therapy in children and young people in hospital (QS131)
This quality standard covers managing intravenous (IV) fluids safely and effectively for babies, children and young people (from birth to 16) in hospital. It describes high-quality care in priority areas for improvement.
View quality statements for QS131Show all sections
Sections for QS131
- Quality statements
- Quality statement 1: Measuring plasma electrolyte concentration and blood glucose
- Quality statement 2: Assessment of fluid balance
- Quality statement 3: Fluid type for intravenous (IV) fluid resuscitation
- Quality statement 4: Fluid type for routine maintenance
- Quality statement 5: Intravenous (IV) fluids lead
- About this quality standard
Evidence-based recommendations on dabrafenib (Tafinlar) plus trametinib (Mekinist) for BRAF V600 mutation-positive advanced non-small-cell lung cancer in adults.
Evidence-based recommendations on imatinib for treating unresectable or metastatic gastrointestinal stromal tumours in adults.
Balloon angioplasty of pulmonary vein stenosis in infants (IPG75)
Evidence-based recommendations on balloon angioplasty of pulmonary vein stenosis in infants. This involves involves inflating a balloon in the narrow section of the pulmonary vein to widen the area so blood can flow through more easily.
View recommendations for IPG75Show all sections
Sections for IPG75
Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis (MIB93)
NICE has developed a medtech innovation briefing (MIB) on the Ekso exoskeleton for rehabilitation in people with neurological weakness or paralysis .
Acalabrutinib with bendamustine and rituximab for untreated mantle cell lymphoma [ID6155]
In development Reference number: GID-TA11091 Expected publication date: TBC
In development Reference number: GID-TA11385 Expected publication date: 25 February 2026
Sotatercept for treating pulmonary arterial hypertension [ID6163]
In development Reference number: GID-TA11103 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on OrganOx metra for liver transplant .
Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest (MIB112)
NICE has developed a medtech innovation briefing (MIB) on Arctic Sun 5000 for therapeutic hypothermia after cardiac arrest .
ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions (MIB295)
NICE has developed a medtech innovation briefing (MIB) on ViewSite Brain Access System (VBAS) for the surgical management of deep brain lesions .
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)
Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.
Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer (TA509)
Evidence-based recommendations on pertuzumab (Perjeta) for treating HER2-positive, locally recurrent or metastatic (secondary) breast cancer that has not been treated with chemotherapy or targeted HER-2 therapy before, in adults.
NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised
Evidence-based recommendations on sebelipase alfa (Kanuma) for long-term enzyme replacement therapy in Wolman disease (rapidly progressive lysosomal acid lipase deficiency) in people aged 2 years and under when treatment starts.
Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)
Evidence-based recommendations on enzalutamide (Xtandi) for treating hormone-sensitive metastatic prostate cancer in adults.
Sorafenib for treating advanced hepatocellular carcinoma (TA474)
Evidence-based recommendations on sorafenib (Nexavar) for treating advanced hepatocellular carcinoma in adults.
In development Reference number: GID-TA11768 Expected publication date: 03 September 2026
In development Reference number: GID-TA11416 Expected publication date: TBC
NICE has developed a medtech innovation briefing (MIB) on AI technologies for detecting diabetic retinopathy .
Evidence-based recommendations on incisionless otoplasty. This involves using a hollow needle to divide the ear cartilage, and using stitches buried under the skin to remould the ear.
View recommendations for IPG422Show all sections
Sections for IPG422
GreenLight XPS for treating benign prostatic hyperplasia (HTG650)
Evidence-based recommendations on GreenLight XPS for treating benign prostatic hyperplasia.
eazyplex SuperBug kits for detecting carbapenemase-producing organisms (MIB94)
NICE has developed a medtech innovation briefing (MIB) on eazyplex SuperBug kits for detecting carbapenemase-producing organisms .
Preventing suicide in community and custodial settings (NG105)
This guideline covers ways to reduce suicide and help people bereaved or affected by suicides. It aims to:
Ambulight PDT for the treatment of non-melanoma skin cancer (HTG268)
Evidence-based recommendations on Ambulight PDT for the treatment of non-melanoma skin cancer.
Ex-situ machine perfusion devices for deceased donor liver transplants
In development Reference number: GID-HTE10066 Expected publication date: 20 August 2026
Actim Pancreatitis for diagnosing acute pancreatitis (MIB218)
NICE has developed a medtech innovation briefing (MIB) on Actim Pancreatitis for diagnosing acute pancreatitis .
Magseed for locating impalpable breast cancer lesions (MIB236)
NICE has developed a medtech innovation briefing (MIB) on Magseed for locating impalpable breast cancer lesions .
NICE has developed a medtech innovation briefing (MIB) on the ATEC breast biopsy system
Service user experience in adult mental health services (QS14)
This quality standard covers improving the experience of people using adult NHS mental health services. It describes high-quality care in priority areas for improvement.
View quality statements for QS14Show all sections
Sections for QS14
- Quality statements
- Quality statement 1: Empathy, dignity and respect
- Quality statement 2: Decision making
- Quality statement 3: Involvement to improve services
- Quality statement 4: Contacts for ongoing care
- Quality statement 5: Access to services
- Quality statement 6: Joint care planning
- Quality statement 7: Inpatient contact with staff
Transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy (IPG484)
Evidence-based recommendations on transoral carbon dioxide laser surgery for primary treatment of oropharyngeal malignancy. This involves using a laser to cut out the tumour and a small amount of the healthy flesh around it.
Evidence-based recommendations on CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack.
Digital technologies to support self-management of COPD: early value assessment (HTG736)
Early value assessment (EVA) guidance on digital technologies to support self-management of COPD.
Radiation dose monitoring software for medical imaging with ionising radiation (MIB127)
NICE has developed a medtech innovation briefing (MIB) on radiation dose monitoring software for medical imaging with ionising radiation .
Evidence-based recommendations on leniolisib (Joenja) for treating activated phosphoinositide 3-kinase delta syndrome in people 12 years and over.
Burosumab for treating X-linked hypophosphataemia in adults (TA993)
Evidence-based recommendations on burosumab (Crysvita) for treating X-linked hypophosphataemia in adults.
NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of
In development Reference number: GID-TA11356 Expected publication date: TBC
HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer (MIB128)
NICE has developed a medtech innovation briefing (MIB) on HTG EdgeSeq ALKPlus Assay EU for ALK status testing in non-small-cell lung cancer .
In development Reference number: GID-TA11254 Expected publication date: 04 March 2026
In development Reference number: GID-TA11774 Expected publication date: 30 September 2026
In development Reference number: GID-TA11823 Expected publication date: TBC
Focal therapy using cryoablation for localised prostate cancer (IPG423)
Evidence-based recommendations on focal therapy using cryoablation for localised stage prostate cancer. This involves using freezing (cryotherapy) needles to find and destroy only the cancerous part of the prostate.
View recommendations for IPG423Show all sections
Sections for IPG423
Diabetes: blood pressure (without moderate or severe frailty) (IND249)
This indicator covers the percentage of patients with diabetes on the register, aged 79 years and under without moderate or severe frailty, in whom the last blood pressure reading (measured in the preceding 12 months) is less than 135/85 mmHg if using ambulatory or home monitoring, or less than 140/90 mmHg if measured in clinic. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM233
MRI fusion biopsy systems for diagnosing prostate cancer (HTG678)
Evidence-based recommendations on MRI fusion biopsy systems for diagnosing prostate cancer.
Early value assessment (EVA) guidance on digital technologies to deliver pulmonary rehabilitation programmes for adults with COPD.